Researchers: Ancillary Services Likely To Add 20% to Medicare Spending on Aduhelm

January 15th 2022

In a research letter published in JAMA Health Forum, researchers say most of the cost figures for Aduhelm have left out the additional MRI scans and other services that will be required because the drug is associated with the development of amyloid-related imaging abnormalities (ARIAs).

In First 2022 Recall, Metformin Pulled Back Because of Carcinogenic NDMA

January 14th 2022

Problems with N-nitrosodimethylamine (NDMA)-contaminated metformin were identified by the FDA in 2020. Viona Pharmaceuticals announced in earlier this month that it was recalling 23 lots of the popular diabetes medication.

Dupixent Has Company. The FDA Has Approved Another Biologic for the Treatment of Atopic Dermatitis.

January 13th 2022

Leo Pharma's Adbry (tralokinumab-ldrm) is the second, FDA-approved biologic for atopic dermatitis. Dupixent (dupilumab) was the first.

Analyst: CMS Decision Will “Significantly Limit" Biogen’s Aduhelm

January 13th 2022

CMS has proposed covering the anti-amyloid treatment only if the person taking it is enrolled in a clinical trial.

Medication Safety Considerations for COVID-19 Treatment Paxlovid

January 11th 2022

Smaller doses are recommended for people with moderate renal impairment and the treatment should not be taken by people with serious kidney disease. There are also drug interactions to be aware of because Paxlovid is an inhibitor of CYP3A.